TY - JOUR
T1 - Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients
AU - van der Sijde, Fleur
AU - Dik, Willem A. A.
AU - Mustafa, Dana A. M.
AU - Vietsch, Eveline E. E.
AU - Besselink, Marc G. G.
AU - Debets, Reno
AU - Koerkamp, Bas Groot
AU - Haberkorn, Brigitte C. M.
AU - Homs, Marjolein Y. V.
AU - Janssen, Quisette P. P.
AU - Luelmo, Saskia A. C.
AU - Mekenkamp, Leonie J. M.
AU - Oostvogels, Astrid A. M.
AU - Smits-te Nijenhuis, Marja A. W.
AU - Wilmink, Johanna W. W.
AU - van Eijck, Casper H. J.
N1 - Funding Information:
This research was funded in part by the Support Casper foundation and by the Eurostars project (project number ESTAR17104).
Publisher Copyright:
Copyright © 2022 van der Sijde, Dik, Mustafa, Vietsch, Besselink, Debets, Koerkamp, Haberkorn, Homs, Janssen, Luelmo, Mekenkamp, Oostvogels, Smits-te Nijenhuis, Wilmink, van Eijck and the Dutch Pancreatic Cancer Group.
PY - 2022/8/25
Y1 - 2022/8/25
N2 - BackgroundBiomarkers predicting treatment response may be used to stratify patients with pancreatic ductal adenocarcinoma (PDAC) for available therapies. The aim of this study was to evaluate the association of circulating cytokines with FOLFIRINOX response and with overall survival (OS). MethodsSerum samples were collected before start and after the first cycle of FOLFIRINOX from patients with PDAC (n=83) of all disease stages. Overall, 34 circulating cytokines were analyzed with a multiplex immunoassay. In addition, changes in peripheral blood immune cell counts were determined by flow cytometry to correlate with differences in cytokine levels. Chemotherapy response was determined by CT scans with the RECIST 1.1 criteria, as disease control (n=64) or progressive disease (n=19) within eight cycles of FOLFIRINOX. ResultsPatients with high serum IL-1RA concentrations after one cycle of chemotherapy were less likely to have tumor progression during FOLFIRINOX (OR 0.25, P=0.040). Increase of circulating IL-1RA concentrations correlated with increase of total, classical (CD14+CD16-), and non-classical monocytes (CD14-CD16+), and dendritic cells. In multivariable cox regression, including the variables chemotherapy response outcome and baseline CA19-9 level, serum concentrations of IL-7 (HR 2.14, P=0.010), IL-18 (HR 2.00, P=0.020), and MIP-1 beta (HR 0.51, P=0.025) after one cycle of FOLFIRINOX showed correlations with OS. ConclusionsCirculating IL-1RA, IL-7, IL-18, and MIP-1 beta concentrations are biomarkers associated with FOLFIRINOX response in PDAC patients, suggesting an important role for specific immune cells in chemotherapy response and PDAC progression. Cytokine-based treatment might improve patient outcome and should be evaluated in future studies.
AB - BackgroundBiomarkers predicting treatment response may be used to stratify patients with pancreatic ductal adenocarcinoma (PDAC) for available therapies. The aim of this study was to evaluate the association of circulating cytokines with FOLFIRINOX response and with overall survival (OS). MethodsSerum samples were collected before start and after the first cycle of FOLFIRINOX from patients with PDAC (n=83) of all disease stages. Overall, 34 circulating cytokines were analyzed with a multiplex immunoassay. In addition, changes in peripheral blood immune cell counts were determined by flow cytometry to correlate with differences in cytokine levels. Chemotherapy response was determined by CT scans with the RECIST 1.1 criteria, as disease control (n=64) or progressive disease (n=19) within eight cycles of FOLFIRINOX. ResultsPatients with high serum IL-1RA concentrations after one cycle of chemotherapy were less likely to have tumor progression during FOLFIRINOX (OR 0.25, P=0.040). Increase of circulating IL-1RA concentrations correlated with increase of total, classical (CD14+CD16-), and non-classical monocytes (CD14-CD16+), and dendritic cells. In multivariable cox regression, including the variables chemotherapy response outcome and baseline CA19-9 level, serum concentrations of IL-7 (HR 2.14, P=0.010), IL-18 (HR 2.00, P=0.020), and MIP-1 beta (HR 0.51, P=0.025) after one cycle of FOLFIRINOX showed correlations with OS. ConclusionsCirculating IL-1RA, IL-7, IL-18, and MIP-1 beta concentrations are biomarkers associated with FOLFIRINOX response in PDAC patients, suggesting an important role for specific immune cells in chemotherapy response and PDAC progression. Cytokine-based treatment might improve patient outcome and should be evaluated in future studies.
UR - http://www.scopus.com/inward/record.url?scp=85137728133&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2022.898498
DO - 10.3389/fimmu.2022.898498
M3 - Article
C2 - 36091056
AN - SCOPUS:85137728133
SN - 1664-3224
VL - 13
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 898498
ER -
